Irreversible EGFR inhibitors in the treatment of advanced NSCLC

Area of Science:

• Oncology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) is a key target in advanced non-small cell lung cancer (NSCLC).
• Current treatments like erlotinib and gefitinib (reversible EGFR tyrosine kinase inhibitors) are effective but lead to acquired resistance.
• EGFR mutations in NSCLC initially respond well to gefitinib and erlotinib, but disease progression occurs within 10-14 months.

Purpose of the Study:

• To review the role of new-generation irreversible EGFR inhibitors in treating advanced NSCLC.
• To evaluate their potential in overcoming acquired resistance to reversible EGFR inhibitors.
• To assess their efficacy as a first-line therapy for EGFR-mutant lung cancers.

Main Methods:

• Review of clinical data on irreversible EGFR inhibitors, specifically afatinib (BIBW 2992) and PF299804.
• Analysis of their use as primary EGFR-targeted therapy.
• Evaluation of their application after resistance develops to reversible EGFR-TKIs.

Main Results:

• Afatinib and PF299804 are prominent irreversible EGFR-TKIs with available clinical data.
• These agents are being investigated for both initial treatment and overcoming resistance in advanced NSCLC.
• Their precise role and long-term impact are still under investigation.

Conclusions:

• Irreversible EGFR inhibitors represent a potential strategy to overcome acquired resistance to gefitinib and erlotinib.
• They may offer improved outcomes compared to reversible inhibitors in EGFR-mutant NSCLC.
• Further definition of their role in clinical practice is necessary.